4.7 Article

STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease

期刊

BLOOD
卷 112, 期 13, 页码 5254-5258

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-03-147322

关键词

-

资金

  1. National Institutes of Health (NIH, Bethesda, MD) [HL69929, CA33049, CA023766, CA107096]
  2. Leukemia & Lymphoma Society (White Plains, NY)
  3. Ryan Gibson Foundation (Dallas, TX)
  4. Emerald Foundation (New York, NY)
  5. Byrne Fund (Etna, NH)
  6. Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
  7. Commonwealth Foundation for Cancer Research (Richmond, VA)
  8. National Marrow Donor Program (NMDP, Minneapolis, MN)
  9. Marrow Foundation (Minneapolis, MN)
  10. NIH [P20-CA103694]
  11. Lymphoma Research Foundation (NewYork, NY)

向作者/读者索取更多资源

Graft-versus-host disease (GVHD) is a serious complication of allogeneic bone marrow transplantation, and donor T cells are indispensable for GVHD. Current therapies have limited efficacy, selectivity, and high toxicities. We used a novel flow cytometry technique for the analysis of intracellular phosphorylation events in single cells in murine BMT models to identify and validate novel GVHD drug targets.(1-7) This method circumvents the requirement for large numbers of purified cells, unlike western blots. We defined a signaling profile for alloactivated T cells in vivo and identified the phosphorylation of ERK1/2 and STAT-3 as important events during T-cell ( allo) activation in GVHD. We establish that interference with STAT-3 phosphorylation can inhibit T-cell activation and proliferation in vitro and GVHD in vivo. This suggests that phosphospecific flow cytometry is useful for the identification of promising drug targets, and ERK1/2 and STAT-3 phosphorylation in alloactivated T cells may be important for GVHD. (Blood. 2008; 112: 5254-5258)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据